MA33127B1 - Composition liposomique - Google Patents

Composition liposomique

Info

Publication number
MA33127B1
MA33127B1 MA34174A MA34174A MA33127B1 MA 33127 B1 MA33127 B1 MA 33127B1 MA 34174 A MA34174 A MA 34174A MA 34174 A MA34174 A MA 34174A MA 33127 B1 MA33127 B1 MA 33127B1
Authority
MA
Morocco
Prior art keywords
liposomes
combination
relates
liposomal composition
eribuline
Prior art date
Application number
MA34174A
Other languages
Arabic (ar)
English (en)
Inventor
Hiroshi Kikuchi
Kenji Hyodo
Hiroshi Ishihara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42828273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33127(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA33127B1 publication Critical patent/MA33127B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE UNE NOUVELLE COMPOSITION LIPOSOMIQUE QUI CONTIENT DE L'ERIBULINE OU UN SEL DE QUALITÉ PHARMACEUTIQUE DE CELUI-CI. L'INVENTION CONCERNE ÉGALEMENT UN PROCÉDÉ DE MISE AU POINT DE CETTE COMPOSITION LIPOSOMIQUE.
MA34174A 2009-03-30 2010-03-30 Composition liposomique MA33127B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16465309P 2009-03-30 2009-03-30
JP2009082521 2009-03-30
PCT/JP2010/055770 WO2010113984A1 (fr) 2009-03-30 2010-03-30 Composition liposomique

Publications (1)

Publication Number Publication Date
MA33127B1 true MA33127B1 (fr) 2012-03-01

Family

ID=42828273

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34174A MA33127B1 (fr) 2009-03-30 2010-03-30 Composition liposomique

Country Status (32)

Country Link
US (3) US20120058178A1 (fr)
EP (1) EP2415470B1 (fr)
JP (1) JP5551683B2 (fr)
KR (1) KR101495951B1 (fr)
CN (1) CN102369008B (fr)
AU (1) AU2010232347A1 (fr)
BR (1) BRPI1014527B8 (fr)
CA (1) CA2756811C (fr)
CO (1) CO6430500A2 (fr)
CY (1) CY1118231T1 (fr)
DK (1) DK2415470T3 (fr)
ES (1) ES2593027T3 (fr)
HR (1) HRP20161157T1 (fr)
HU (1) HUE029577T2 (fr)
IL (1) IL215059A (fr)
LT (1) LT2415470T (fr)
MA (1) MA33127B1 (fr)
ME (1) ME02518B (fr)
MX (1) MX2011009632A (fr)
MY (1) MY160203A (fr)
NZ (1) NZ595212A (fr)
PE (2) PE20151519A1 (fr)
PL (1) PL2415470T3 (fr)
PT (1) PT2415470T (fr)
RS (1) RS55148B1 (fr)
SG (1) SG174255A1 (fr)
SI (1) SI2415470T1 (fr)
SM (1) SMT201600307B (fr)
TW (1) TWI392519B (fr)
UA (1) UA103794C2 (fr)
WO (1) WO2010113984A1 (fr)
ZA (1) ZA201106535B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
WO2010113983A1 (fr) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé de mise au point d'une composition liposomique
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
JP2014508165A (ja) 2011-03-02 2014-04-03 モルフォテック、インク． 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
WO2014121211A2 (fr) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Chargement à distance de médicaments médiocrement solubles dans l'eau dans des liposomes
CN106999419A (zh) 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 远程装载略微水溶性药物至脂质膜泡
EP3265063A4 (fr) 2015-03-03 2018-11-07 Cureport, Inc. Formulations pharmaceutiques liposomales à double charge
SI3350222T1 (sl) 2015-09-18 2022-01-31 Technische Universitaet Muenchen Ligandi za integrin avbeta6, sinteza in uporaba le-teh
EP3372223B1 (fr) 2015-11-02 2024-04-17 FUJIFILM Corporation Composition liposomale et son procédé de production
WO2017188350A1 (fr) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé d'inhibition de croissance tumorale
US11331272B2 (en) 2017-01-18 2022-05-17 Temasek Life Sciences Laboratory Limited Hyperstabilized liposomes increase targeting of mitotic cells
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
RU2734900C1 (ru) * 2017-03-31 2020-10-26 Фуджифилм Корпорэйшн Липосомальная композиция и фармацевтическая композиция
WO2019097073A1 (fr) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Associations pharmaceutiques destinées à être utilisées dans le traitement du cancer
MA51514A (fr) * 2018-01-02 2021-04-07 Scynexis Inc Compositions injectables d'antifongiques triterpénoïdes encapsulées dans des liposomes
PL3811931T3 (pl) 2018-06-20 2024-11-18 Fujifilm Corporation Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
TWI837189B (zh) 2018-10-01 2024-04-01 日商富士軟片股份有限公司 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US20230201119A1 (en) * 2020-05-29 2023-06-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Liposome containing ethylenediamine tetraacetic acid or salt thereof and eribulin or pharmaceutically acceptable salt thereof
GB2626483A (en) * 2021-10-14 2024-07-24 Pacira Pharmaceuticals Inc Multivesicular liposome formulations of dexamethasone
CN115957351B (zh) * 2022-11-15 2023-06-27 中国人民解放军海军第九七一医院 一种碘海醇注射液及其制备方法
CN121001745A (zh) * 2023-03-30 2025-11-21 上海济昀生物科技有限公司 一种磷脂组合物及其制备方法及含氮化合物的应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
FR2736056B1 (fr) 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
AU2002340670A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DE10255106A1 (de) 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
BR0317882A (pt) 2002-12-31 2005-12-13 Bharat Serums & Vaccines Ltd Processo para fabricação de lipossomas de longa circulação não tratados com peg; lipossoma; composição de doxorrubicina lipossomal de longa duração não tratada com peg; e método
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP1618897A4 (fr) * 2003-04-04 2010-09-29 Eisai R&D Man Co Ltd Structure de membrane lipidique comportant un anticorps monoclonal anti-mt-mmp
US6747011B1 (en) 2003-06-04 2004-06-08 A.P. Group, Inc. Antitumor drugs and methods
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
CA2553573A1 (fr) 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. Methode de stabilisation d'un compose de macrolide
LT3173073T (lt) * 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
EP1750673B1 (fr) 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Formulations liposomales comprenant de la dihydrosphingomyéline, et procedés d'utilisation correspondants
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
WO2006037230A1 (fr) 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes permettant une meilleure retention du medicament, destines au traitement du cancer
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090196913A1 (en) 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
US20090196917A1 (en) 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (fr) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2010113983A1 (fr) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé de mise au point d'une composition liposomique
RU2476216C1 (ru) 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
RU2405601C1 (ru) 2009-05-19 2010-12-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения злокачественных опухолей мочевого пузыря
JP5388735B2 (ja) 2009-07-21 2014-01-15 浜松ホトニクス株式会社 マイクロチャンネルプレート
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
JP2014508165A (ja) 2011-03-02 2014-04-03 モルフォテック、インク． 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
EP2686441B1 (fr) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Procédé et utilisation pour prédire la réponse à l'éribuline
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
EP2693875A4 (fr) 2011-04-08 2014-10-22 British Columbia Cancer Agency Composés de bisphénol et leurs procédés d'utilisation
AU2012284147A1 (en) 2011-07-19 2014-02-27 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
RU2689977C2 (ru) 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
WO2014159562A1 (fr) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combinaison d'agoniste de dr5 et d'antagoniste anti-pd-1 et méthodes d'utilisation associées
ES2822665T3 (es) 2013-05-31 2021-05-04 Merck Sharp & Dohme Terapias de combinación para el cáncer
CA2912346A1 (fr) 2013-06-11 2014-12-18 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de pi3k et d'un destabilisateur de microtubule
BR112015029386B1 (pt) 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
WO2015042279A1 (fr) 2013-09-18 2015-03-26 Stc. Unm Nanoparticules de silice mésoporeuse toroïdales (tmsnp) et proto-cellules associées
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US20170020817A1 (en) 2013-12-19 2017-01-26 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtuble inhibitors with reduced ostwald repening for oral administration
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
CA2940983A1 (fr) 2014-03-03 2015-09-11 Eisai R&D Management Co., Ltd. Utilisation d'eribuline et d'inhibiteurs de mtor en tant que polytherapie pour le traitement du cancer
KR20240144452A (ko) 2014-03-05 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
US20170100367A1 (en) 2014-05-28 2017-04-13 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
WO2015184145A1 (fr) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Utilisation de l'éribuline et des inhibiteurs de la poly(adp-ribose) polymérase (parp) en tant que que polythérapie pour le traitement du cancer
MA40921A (fr) 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
CN105640935A (zh) 2014-11-12 2016-06-08 天津市汉康医药生物技术有限公司 供注射用甲磺酸艾日布林药物组合物
JP2016133331A (ja) 2015-01-16 2016-07-25 ソニー株式会社 電気的測定用カートリッジ、生体試料用電気的測定装置及び生体試料用電気的測定方法
CN117100753A (zh) 2015-02-12 2023-11-24 大连万春布林医药有限公司 普那布林联合免疫检查点抑制剂的用途
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
WO2017188350A1 (fr) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé d'inhibition de croissance tumorale
WO2018071792A1 (fr) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combinaison d'un antagoniste de pd-1 et d'éribuline dans le traitement du cancer urothélial
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Also Published As

Publication number Publication date
CO6430500A2 (es) 2012-04-30
PE20151519A1 (es) 2015-10-28
WO2010113984A1 (fr) 2010-10-07
BRPI1014527B1 (pt) 2020-11-24
NZ595212A (en) 2014-02-28
ME02518B (fr) 2017-02-20
PL2415470T3 (pl) 2016-12-30
UA103794C2 (en) 2013-11-25
SMT201600307B (it) 2016-11-10
CY1118231T1 (el) 2017-06-28
PT2415470T (pt) 2016-08-31
HUE029577T2 (en) 2017-03-28
JP5551683B2 (ja) 2014-07-16
HK1165707A1 (en) 2012-10-12
AU2010232347A1 (en) 2011-09-29
CN102369008A (zh) 2012-03-07
US11071713B2 (en) 2021-07-27
RS55148B1 (sr) 2016-12-30
US20140044777A1 (en) 2014-02-13
BRPI1014527A2 (pt) 2016-04-05
SG174255A1 (en) 2011-10-28
EP2415470A1 (fr) 2012-02-08
IL215059A (en) 2016-03-31
BRPI1014527B8 (pt) 2021-05-25
CN102369008B (zh) 2014-10-29
EP2415470A4 (fr) 2012-11-28
EP2415470B1 (fr) 2016-07-06
SI2415470T1 (sl) 2016-12-30
DK2415470T3 (en) 2016-09-19
KR101495951B1 (ko) 2015-02-25
US12042560B2 (en) 2024-07-23
MX2011009632A (es) 2011-10-19
ES2593027T3 (es) 2016-12-05
US20120058178A1 (en) 2012-03-08
TWI392519B (zh) 2013-04-11
CA2756811A1 (fr) 2010-10-07
US20210023004A1 (en) 2021-01-28
LT2415470T (lt) 2016-10-10
MY160203A (en) 2017-02-28
HRP20161157T1 (hr) 2016-11-18
PE20120923A1 (es) 2012-08-27
IL215059A0 (en) 2011-11-30
JPWO2010113984A1 (ja) 2012-10-11
TW201102110A (en) 2011-01-16
KR20110122219A (ko) 2011-11-09
CA2756811C (fr) 2014-09-23
ZA201106535B (en) 2012-05-30

Similar Documents

Publication Publication Date Title
MA33127B1 (fr) Composition liposomique
MA37379A1 (fr) Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
MA35359B1 (fr) Lutte biologique contre les nématodes
UA110197C2 (ru) Соединения, эффективные как ингибиторы для ксантиноксидазы, процесса получения таких соединений и фармацевтической композиции, содержащей терапевтически эффективное количество таких соединений.
MA33826B1 (fr) Analogue du peptide d'oxyntomoduline
MX340572B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
PT1913001E (pt) (r)-n-metilnaltrexona, processos para a sua síntese e sua utilização farmacêutica
WO2010048477A3 (fr) Procede ameliore de preparation de produits couples a partir de 4-amino-3-cyanoquinoleines utilisant des intermediaires stabilises
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
MX353461B (es) PROCESOS PARA PREPARAR COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA ATAXIA TELANGIECTASIA MUTADA Y Rad3 RELACIONADOS (ATR).
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
UA107574C2 (ru) Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида
MA55193B1 (fr) Procédés de préparation d'un inhibiteur de pi3k
EA201291413A1 (ru) Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MA31603B1 (fr) Nouvelle forme cristalline du 3-(difluorométhyle)-1-méthyle-n-(3',4',5'-trifluoro[1,1'-biphenyl]-2-yl)-1h-pyrazole-4-carboxamide
MX2008012424A (es) Proceso convergente para la sintesis de derivados de taxanos.
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
TNSN08244A1 (en) Process for the preparation of ferri-succinylcasein
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов
FR2940289B1 (fr) Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
DE602007007618D1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis